{"filings":[{"id":1977038,"accession_number":"0001682852-26-000147","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-07-31T11:03:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.","2026 guidance: targeting up to 10% revenue growth; year-end cash improved to $4.7-5.2B; R&D expense lowered to ~$2.9B.","Norovirus vaccine mRNA-1403 failed early success criteria at Phase 3 interim; enrolling additional cohort.","mFLUSIVA (flu vaccine) PDUFA date Aug 5, 2026; potential fifth approved product.","Appointed Ester Banque as CCO and Michael McDonnell to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1508076,"accession_number":"0001682852-26-000134","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-07-08T11:08:16+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints former Biogen CFO Michael McDonnell to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael McDonnell appointed to Moderna's Board, effective July 8, 2026; will serve on Audit Committee.","McDonnell served as Biogen CFO from Aug 2020 to Feb 2025; also CFO of IQVIA, Intelsat, MCG Capital, EchoStar.","David Rubenstein moved off Audit Committee to Nominating and Corporate Governance Committee.","McDonnell will receive standard non-employee director compensation including initial and pro-rata annual grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94671,"accession_number":"0001682852-26-000101","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Moderna amends bylaws for federal forum exclusivity; stockholders re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved bylaw amendment designating federal district courts as exclusive forum for Securities Act claims, effective immediately.","Stockholders re-elected Sandra Horning, M.D. and Abbas Hussain as Class II directors for three-year terms.","Say-on-pay advisory vote passed with 169M for, 90.8M against; company will hold annual advisory votes.","Ratification of Ernst & Young as independent auditor for FY 2026 approved with 298.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94670,"accession_number":"0001682852-26-000057","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 2026 revenue $389M, GAAP net loss $(1.3)B including $0.9B litigation charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $389M (+$281M YoY); ~80% from international; GAAP EPS $(3.40) vs $(2.52) YoY.","Net loss $(1.3)B includes $0.9B non-recurring litigation settlement charge; cash $7.5B.","Reaffirms up to 10% revenue growth in 2026; cost of sales guidance ~$1.8B including charge.","EU approved mNEXSPIKE and mCOMBRIAX (flu+COVID combo); Phase 3 initiated for intismeran in NSCLC.","R&D expenses down 24% YoY to $649M; SG&A down 18% to $173M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":389000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107226,"accession_number":"0001682852-26-000047","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Moderna settles all patent litigation with Arbutus/Genevant for $950M upfront, up to $1.3B contingent","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Moderna to pay $950M noncontingent lump sum by July 8, 2026 to resolve worldwide patent litigation over Spikevax and mRESVIA.","Additional $1.3B contingent payment due if Moderna loses appeal on Section 1498 government contractor defense at Federal Circuit.","Settlement includes fully paid-up, royalty-free license for Moderna's infectious disease vaccines using SM-102 LNP (Spikevax, mNEXSPIKE, mRESVIA, future pipeline).","Moderna may appeal Section 1498 issue; if partially successful, prorated amount of $1.3B may be due; if fully successful, no further payment.","Agreement provides mutual releases and dismissals of all pending claims in U.S. and international litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107225,"accession_number":"0001682852-26-000015","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).","Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).","2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.","U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.","Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1944000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107224,"accession_number":"0001682852-26-000012","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Moderna receives FDA Refusal-to-File for flu vaccine mRNA-1010; no impact on 2026 guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CBER refused to review BLA for mRNA-1010 citing comparator choice, not safety/efficacy.","Moderna states RTF letter contradicts prior written feedback from pre-Phase 3 and pre-submission meetings.","Moderna has requested a Type A meeting with FDA to discuss path forward.","mRNA-1010 accepted for review in EU, Canada, Australia; earliest approval late 2026/early 2027.","Company reaffirms no change to 2026 financial guidance despite RTF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107223,"accession_number":"0001682852-26-000007","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna reports prelim 2025 rev ~$1.9B, cuts OpEx guidance, expects flu/COVID combo approvals in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 preliminary revenue ~$1.9B ($100M above midpoint); GAAP OpEx $5.0-5.2B (improved $200M).","Year-end cash ~$8.1B including $0.6B draw from new $1.5B Ares term loan facility.","2026 targets: up to 10% revenue growth, $4.9B GAAP OpEx; 2027 OpEx $4.2-4.6B, path to cash breakeven 2028.","Expects 2026 approvals of flu vaccine mRNA-1010 and flu/COVID combo mRNA-1083; multiple pivotal readouts in oncology/rare disease.","Closed $1.5B term loan from Ares; CEPI commits $54.3M for H5 pandemic flu vaccine Phase 3 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107222,"accession_number":"0001682852-26-000003","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna projects 2025 revenue $1.6-2.0B, targets up to 10% growth in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance of $1.6-2.0B; cash costs beat commitments by nearly $1B.","mNEXSPIKE captured ~24% of U.S. retail COVID shots and ~33% of 65+ segment.","Secured $1.5B five-year term loan; GAAP opex to fall below $5.5B in 2025 from $7.2B in 2024.","Cash cost target: ~$4.2B in 2026 and $3.5-3.9B in 2027; cash breakeven targeted in 2028.","Pipeline: Phase 3 flu efficacy positive; intismeran Phase 2b data and nine oncology readouts expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123559,"accession_number":"0001628280-25-053816","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Moderna enters $1.5B credit facility with Ares; $600M initial term loan, $900M delayed draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1.5B facility: $600M initial term loan and $900M delayed draw tranche available through Nov 2027/2028.","Interest at Term SOFR + 5.50% or base rate + 4.50%; maturity date November 24, 2030.","Secured by all assets of Moderna; guaranteed by US, Canadian, UK, Swiss, and Australian subsidiaries.","Minimum liquidity covenant of $500M ($750M if >$1B drawn); not tested if market cap >$5B.","Proceeds used for general corporate purposes; loan contingent on regulatory milestones for delayed draw portion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123558,"accession_number":"0001628280-25-053318","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna targets up to 10% revenue growth in 2026; closes $1.5B loan facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Targets up to 10% revenue growth in 2026; expanding seasonal vaccine franchise to up to six approved products by 2028.","Reducing 2026 and 2027 GAAP operating expenses by ~$0.5B each year on path to cash breakeven in 2028.","Closed a five-year $1.5B term loan facility from Ares Management Credit Funds; initial draw $0.6B.","Discontinues four pipeline programs: CMV, HSV, VZV, and GSD1a; advances nine oncology Phase 2/3 studies.","Updated 2025 year-end cash guidance to $7.1-$7.6B (from $6.5-$7.0B) due to loan draw."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123557,"accession_number":"0001628280-25-052055","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna shareholders approve one-time stock option exchange program for non-Exec Committee employees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (option exchange) passed: 231,049,158 votes for, 6,167,159 against, 250,409 abstain.","Proposal 2 (adjournment if needed) passed: 223,991,059 for, 13,198,386 against, 277,281 abstain.","No broker non-votes reported; special meeting held November 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123556,"accession_number":"0001682852-25-000073","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.","2025 revenue range narrowed to $1.6-2.0B; GAAP opex cut by $0.7B to $5.2-5.4B.","Year-end cash target raised by $0.5-1.0B to $6.5-7.0B; Q3-end cash $6.6B.","COVID vaccine sales $971M; RSV mRESVIA sales $2M; mNEXSPIKE launched in US.","Discontinues congenital CMV program after Phase 3 missed primary endpoint; norovirus study extends."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1266000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140238,"accession_number":"0001682852-25-000041","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $0.8B, rev $142M (-41% YoY); cuts 2025 revenue guidance high end by $300M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $142M (-41% YoY); GAAP net loss $0.8B ($2.13 EPS loss).","2025 revenue guidance narrowed to $1.5-$2.2B (high end cut $300M due to UK delivery timing shift to 2026).","GAAP operating expenses expected $5.9-$6.1B, improved ~$400M; year-end cash ~$6B reiterated.","Announced three FDA approvals (mNEXSPIKE for high-risk adults, Spikevax for children, mRESVIA for 18-59) and positive Phase 3 flu vaccine efficacy data.","Restructuring: global workforce reduction of ~10%, targeting headcount under 5,000 by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":250000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157888,"accession_number":"0001682852-25-000036","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna shareholders re-elect board, approve executive compensation, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors re-elected: Bancel 245.5M for (5.2M against); Afeyan 218.6M for (32.1M against); Nader 195.4M for (55.2M against).","Advisory 'say-on-pay' passed with 192.3M for, 56.5M against, 43.3M broker non-votes.","Ratification of Ernst & Young as auditor for FY2025 approved with 290.7M for, 3.2M against.","Broker non-votes of 43.3M were present on all director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157887,"accession_number":"0001682852-25-000031","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 net loss $1.0B, revenue $108M; reiterates 2025 revenue guidance $1.5-2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 revenue $108M (down 35% YoY); GAAP net loss $(1.0)B, EPS $(2.52).","Reiterates 2025 revenue guidance $1.5-2.5B; expects H1 revenue ~$0.2B due to seasonality.","Announces cost-cutting plan: reduce GAAP operating costs by $1.4-1.7B by 2027; new 2027 estimate $4.7-5.0B.","Pipeline milestones: next-gen COVID vaccine PDUFA May 31; RSV vaccine PDUFA June 12; flu/COVID combo approval targeted 2026.","Cash and investments $8.4B at March 31 (down from $9.5B at Dec 31); expects year-end ~$6B."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":108000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176268,"accession_number":"0001682852-25-000006","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q4 net loss $1.1B, EPS $(2.91); FY2024 revenue $3.2B falls 53%; guides 2025 rev $1.5-2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.0B (-66% YoY); GAAP net loss $1.1B vs net income $217M in Q4 2023.","FY2024 revenue $3.2B (-53% YoY); GAAP net loss $3.6B; EPS $(9.28).","FY2024 cost of sales 47% of net product sales, including $238M non-cash charge for manufacturing agreement termination.","2025 revenue guided $1.5-2.5B; expects first-half 2025 revenue only ~$0.2B due to seasonality.","Filed three BLAs: next-gen COVID (PDUFA May 31), RSV for 18-59 (PDUFA June 12), flu/COVID combo."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":3236000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176267,"accession_number":"0001682852-25-000002","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna: 2024 sales $3.0-3.1B; 2025 revenue guided $1.5-2.5B, down ~40%; CMV trial misses early efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2024 product sales ~$3.0-3.1B (unaudited); cash & investments ~$9.5B. Full 2024 results due Feb 14, 2025.","2025 revenue guidance $1.5-2.5B (mostly H2); expects year-end cash ~$6.0B.","Accelerating cost cuts: $1B cash-cost reduction in 2025, additional $0.5B in 2026.","CMV vaccine Phase 3 DSMB: early efficacy not met; study continues blinded. Final data expected 2025.","Next-gen COVID BLA accepted (PDUFA May 31, 2025); RSV vaccine for high-risk adults filed; flu/COVID combo filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193159,"accession_number":"0001682852-24-000057","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net income $13M, revenue $1.9B; reiterates FY product sales $3-3.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $13M ($0.03 EPS) vs net loss of $3.6B in Q3 2023; revenue $1.9B.","Net product sales $1.8B (+4% YoY); COVID-19 sales $1.8B, RSV sales $10M (below expectations).","FY 2024 product sales guidance reiterated at $3.0-3.5B; cost of sales guidance narrowed to 40-45%.","R&D lowered to $4.6-4.7B; capex raised to ~$1.2B including Norwood campus purchase ($0.4B).","Initiated Phase 3 trials for norovirus and influenza vaccines; expanded Executive Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2270000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193158,"accession_number":"0001682852-24-000052","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints Abbas Hussain, ex-CEO of Vifor Pharma, to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hussain appointed effective Oct 2, 2024; board size fixed at nine directors.","He brings over 35 years of healthcare leadership, including former CEO of Vifor Pharma and Global President of GSK Pharmaceuticals & Vaccines.","Hussain will serve on the Audit Committee and receive standard non-employee director compensation plus initial and pro-rata annual equity grants.","No arrangements or relationships requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209534,"accession_number":"0001682852-24-000049","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna outlines 10 product approvals by 2027; cuts R&D spend, issues 2025 revenue guidance $2.5-3.5B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Expects ten product approvals through 2027, including three respiratory vaccine submissions in 2024 (next-gen COVID, flu/COVID combo, RSV for high-risk adults).","Positive Phase 3 results for RSV vaccine in high-risk adults 18-59; sBLA filing planned in 2024 using Priority Review Voucher.","Cuts cumulative R&D spend for 2025-2028 by 20% to $16B; 2025 R&D guidance $4.2-4.5B; 2025 revenue guidance $2.5-3.5B.","Norovirus vaccine mRNA-1403 advances to Phase 3; INT melanoma Phase 3 substantially enrolled but FDA not supportive of accelerated approval.","Five pipeline programs discontinued; plans to break even on operating cash cost basis in 2028 with $6B revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209533,"accession_number":"0001682852-24-000043","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $1.3B, EPS $(3.33); cuts 2024 product sales forecast to $3.0-3.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $241M vs $344M YoY; net product sales $184M (-37%).","Revised FY2024 product sales guidance to $3.0-3.5B; cites low EU sales, deferrals, competitive US market.","RSV vaccine mRESVIA approved by FDA, shipping since July; EMA positive opinion.","Phase 3 data positive for combo flu+COVID and next-gen COVID vaccines; filings planned in 2024.","David Rubenstein joins Board Aug 5; Robert Langer and Stephen Berenson retire."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":408000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209532,"accession_number":"0001682852-24-000035","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints David Rubenstein to board; co-founders Langer and Berenson retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Rubenstein (Carlyle Co-Founder) joins Moderna board effective Aug 5, 2024, replacing Stephen Berenson on Audit Committee.","Robert Langer and Stephen Berenson will retire from board on Aug 5, 2024; both will provide advisory services through Nov 1, 2026.","Dr. Langer's and Mr. Berenson's resignations not due to any disagreement with Moderna's operations or policies.","Board size fixed at eight directors; search ongoing for replacement with scientific/innovation experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227618,"accession_number":"0001682852-24-000031","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Moderna shareholders approve special meeting right and officer exculpation amendments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved right for holders of at least 20% of shares to call a special meeting.","Shareholders approved officer exculpation amendment under new Delaware law provisions.","All three Class III directors (Langer, Nabel, Tallett) elected with strong support.","Say-on-pay and ratification of EY as auditor each passed with overwhelming majorities.","Amendments and restated certificate became effective upon filing with Delaware Secretary of State on May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227617,"accession_number":"0001682852-24-000023","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 revenue $167M, net loss $1.2B; reaffirms FY 2024 sales ~$4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $1.2B and diluted EPS of $(3.07) vs. $0.19 EPS a year ago.","Spikevax product sales fell 91% YoY to $167M; $100M U.S., $67M international.","Reaffirms 2024 product sales ~$4B; expects ~$0.3B net sales in H1 2024.","Cash and investments $12.2B at March 31, down from $13.3B at year-end 2023.","RSV vaccine launch targeted for fall 2024; flu vaccine filing expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":167000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246416,"accession_number":"0001682852-24-000010","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q4 2023 revenue $2.8B, EPS $0.55; FY net loss $4.7B from $3.7B non-cash charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.8B (-43% YoY); GAAP net income $217M, diluted EPS $0.55.","FY2023 revenue $6.8B; GAAP net loss $4.7B, diluted EPS ($12.33) from $3.7B non-cash charges (resizing, valuation allowance).","Reaffirms 2024 product sales ~$4B; expects RSV vaccine (mRNA-1345) regulatory approvals beginning H1 2024 (PDUFA May 12).","FY2023 COVID vaccine sales $6.7B; U.S. retail market share 48% (vs 37% in 2022).","2024 guidance: cost of sales ~35% of product sales; R&D ~$4.5B; SG&A ~$1.3B; year-end cash ~$9B."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":6848000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246415,"accession_number":"0001682852-24-000004","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna reports preliminary 2023 product sales ~$6.7B; guides 2024 sales ~$4B, targets break-even 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2023 COVID-19 vaccine product sales ~$6.7B (incl. $0.6B deferred revenue from GAVI).","Cash, cash equivalents & investments >$13B at Dec 31, 2023.","2024 product sales guidance ~$4B, mostly H2; targets break-even by 2026.","RSV vaccine regulatory filings submitted; expects approvals beginning H1 2024.","U.S. COVID-19 market share season-to-date 48% (up from 37% in 2022)."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":6848000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263849,"accession_number":"0001682852-23-000049","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Moderna CCO Arpa Garay departs; CEO & President to oversee commercial org","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Arpa Garay no longer serves as Chief Commercial Officer effective Dec 8, 2023.","Commercial organization will be overseen by CEO Stéphane Bancel and President Stephen Hoge.","Garay to remain as employee through June 2024 in advisory capacity for transition.","Severance includes 12 months salary ($850,000), target bonus ($765,000), and COBRA.","Accelerated vesting of 15% of unvested time-based equity awards, plus 12-month option exercise window."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263848,"accession_number":"0001682852-23-000044","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Moderna CCO cancels 10b5-1 trading plan; no trades executed","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Arpa Garay, Chief Commercial Officer, adopted a 10b5-1 plan on August 24, 2023.","Plan cancelled on November 6, 2023, following disclosure of Q3 2023 results.","Sales under the plan were to begin no earlier than November 27; no shares sold or options exercised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263847,"accession_number":"0001682852-23-000038","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net loss $3.6B on $1.8B revenue; guides 2024 sales ~$4B, aims for 2026 breakeven","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $1.8B, down 44% YoY; net loss $3.6B vs net income $1.0B; diluted EPS -$9.53.","Non-cash charges of $3.1B: $1.3B inventory write-downs, $0.5B contract manufacturing wind-down, $1.7B tax valuation allowance.","2023 product sales guidance at least $6B; 2024 sales projected ~$4B; expects breakeven in 2026.","COVID-19 U.S. market share rose to 45% (from 36%); RSV vaccine BLA filed with FDA, launch expected 2024.","Cash and investments $12.8B; plans to fund without raising equity."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":4037000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263846,"accession_number":"0001682852-23-000033","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Moderna reaffirms FY2023 COVID-19 vaccine revenue guidance of $6-8B; provides scenario-based range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 COVID-19 vaccine revenue guidance unchanged at $6B-$8B.","If U.S. market is ~50M doses, expects to be in bottom half of range.","If U.S. market is ~100M doses, expects to be in top half of range.","Too early to project; better visibility after October vaccination trends.","Will provide an update at the November 2 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":4037000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281066,"accession_number":"0001682852-23-000030","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna and Immatics announce $120M upfront oncology collaboration for TCR bispecifics and cancer vaccines","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Immatics receives $120M upfront plus research funding; milestones could exceed $1.7B plus tiered royalties on net sales.","Collaboration spans three pillars: mRNA-expressed TCER bispecifics, novel mRNA cancer vaccines using XPRESIDENT, and IMA203 TCR-T combo with Moderna's PRAME vaccine.","Moderna leads clinical development and commercialization of TCER and vaccine products; Immatics handles preclinical/Phase 1 for the combo study.","Immatics holds option to enter global profit/loss share for the most advanced TCER program.","Deal subject to customary US antitrust clearance; Moderna retains full ownership of its PRAME compound."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281065,"accession_number":"0001682852-23-000025","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.","Net loss $1.4B vs net income $2.2B YoY; diluted EPS -$3.62 vs +$5.24.","Cost of sales $731M includes $464M inventory write-downs, $135M unutilized capacity, $75M purchase commitment losses.","Guides FY23 COVID vaccine sales $6-8B; expects ~$1B of APAs deferred to 2024; cost of sales now $3.5-4B.","RSV vaccine submitted globally for approval; Phase 3 melanoma combo trial with Merck initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":2206000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299773,"accession_number":"0001193125-23-137079","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna Stockholders Elect Three Class II Directors and Approve Executive Compensation at 2023 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Stephen Berenson (226.6M for, 64.2M withheld), Sandra Horning (281.8M for, 8.9M withheld), and Paul Sagan (219.0M for, 71.7M withheld) as Class II directors.","Advisory vote on named executive officer compensation approved with 254.1M for, 34.9M against, and 1.6M abstentions.","Ratification of Ernst & Young as independent auditor for 2023 approved with 352.0M for, 3.9M against, and 0.2M abstentions.","Shareholder proposal requesting report on feasibility of transferring intellectual property defeated: 21.4M for, 268.0M against, 1.3M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299772,"accession_number":"0001682852-23-000018","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 revenue $1.9B, net income $79M, reiterates $5B FY sales guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.9B (down 69% YoY); GAAP net income $79M ($0.19 EPS) vs $3.7B ($8.58 EPS) in Q1 2022.","Cost of sales 43% of product sales vs 17% prior year; includes $148M inventory write-downs and $135M idle capacity charges.","R&D spending surged 104% to $1.1B, driven by RSV, flu, CMV programs; total 2023 OpEx guided ~$6B.","RSV vaccine (mRNA-1345) met primary endpoint in older adults; expects regulatory submission and 2024 launch.","COVID-19 vaccine sales from APAs still projected at $5B for 2023; Q2 sales expected $0.2-0.3B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1862000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319875,"accession_number":"0001682852-23-000008","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q4 net income down 70% to $1.5B; FY2022 revenue $19.3B; reiterates $5B COVID sales for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $5.1B (down 29% YoY from $7.2B); GAAP diluted EPS $3.61 (down 68% from $11.29).","Full-year 2022 revenue $19.3B (up 4% from $18.5B); GAAP net income $8.4B (down 31% from $12.2B); diluted EPS $20.12.","Cost of sales surged to 39% of product sales in Q4 (from 14% YoY) due to $297M inventory write-downs, $281M purchase commitment losses, $376M unutilized capacity charges.","R&D spending increased 87% to $1.2B in Q4; full-year R&D $3.3B (up 65%); 2023 R&D guidance $4.5B.","Juan Andres, President of Strategic Partnerships, to retire in May 2023; Jerh Collins joined as CTOO in October 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":20.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":19263000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319874,"accession_number":"0001682852-23-000004","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Moderna reports prelim 2022 COVID sales $18.4B; reiterates 2023 $5B min; RSV study accrues cases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prelim 2022 COVID vaccine sales ~$18.4B; R&D ~$3.3B; cash & investments >$18B.","2023 min COVID sales reiterated at ~$5B; R&D budget rises to ~$4.5B.","RSV vaccine (mRNA-1345) Phase 3 in older adults accrued enough cases for first interim efficacy analysis.","Personalized cancer vaccine mRNA-4157 + Keytruda reduced recurrence risk by 44% in melanoma; Phase 3 to start 2023.","Repurchased 23M shares for $3.3B in 2022; $2.8B remaining; acquired OriCiro Genomics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319873,"accession_number":"0001682852-23-000002","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna details 2023 strategic priorities; RSV trial nearly enrolled, flu vaccine accelerated pathway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RSV vaccine Phase 3 enrolled >36,000 of 37,000 target; flu vaccine efficacy trial initiated in Northern Hemisphere.","Personalized cancer vaccine (mRNA-4157/V940) + KEYTRUDA cut recurrence or death risk by 44% in Phase 2 melanoma study.","First inhaled mRNA candidate (Vxc-522 for cystic fibrosis) cleared by FDA; relaxin Phase 1B dosed for heart failure.","Rare disease programs show promise: propionic acidemia MDE reductions; sixth candidate (OTC deficiency) added.","2023 priorities include building respiratory franchise, aggressive cancer vaccine program, and potential flu vaccine approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338089,"accession_number":"0001682852-22-000055","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna and Merck report Phase 2b mRNA cancer vaccine met primary endpoint in melanoma, reducing recurrence risk by 44%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["mRNA-4157/V940 + KEYTRUDA reduced risk of recurrence or death by 44% vs KEYTRUDA alone (HR=0.56, p=0.0266) in stage III/IV melanoma.","First randomized trial evidence for an mRNA cancer treatment; companies plan Phase 3 in melanoma in 2023 and expansion to other tumor types.","Serious treatment-related AEs: 14.4% in combination arm vs 10% with KEYTRUDA alone.","Merck and Moderna share costs and profits equally under worldwide collaboration announced in October."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338088,"accession_number":"0001682852-22-000049","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q3 net income $1.0B, EPS $2.53; lowers 2022 sales view to $18-19B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $3.4B (down 32% YoY), GAAP net income $1.0B, diluted EPS $2.53 (down 67%).","Product sales $3.1B, down 35%; cost of sales 35% including $333M write-downs and $209M unutilized capacity.","2022 sales guidance lowered to $18-19B ($2-3B deferred to 2023); 2023 preliminary APAs $4.5-5.5B.","Completed $3B buyback; new $3B program underway; cash $17.0B.","Pipeline: PCV Phase 2 data Q4 2022; RSV Phase 3 data this winter; flu Phase 3 data Q1 2023; $250M from Merck."],"consensus_eps_estimate":null,"consensus_eps_actual":16.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":14179000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355447,"accession_number":"0001682852-22-000045","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints Andres to new President role, Collins as CTOQO effective Jan 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Juan Andres transitions to President, Strategic Partnerships and Enterprise Expansion; retains Executive Committee seat.","Jerh Collins joins as Chief Technical Operations & Quality Officer, effective Jan 1, 2023; from Novartis with 30 yrs manufacturing experience.","Executive Committee expanded to prepare for multiple new product launches; Andres led COVID vaccine production.","Collins will focus on expanding production footprint globally; starts Oct 3, 2022, assumes role Jan 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355446,"accession_number":"0001193125-22-223286","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints James Mock as CFO effective Sept 6, 2022; David Meline retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Mock named CFO, starting Sept 6, 2022; will report to CEO Stéphane Bancel.","David Meline retires as CFO same date but remains as consultant for transition.","Mock receives $750,000 base salary, $1M signing bonus, $6M equity grant (4-yr vest).","Mock previously SVP & CFO of PerkinElmer; 20 years at GE before that."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355445,"accession_number":"0001682852-22-000040","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q2 revenue $4.7B, GAAP EPS $5.24, announces $3B buyback, reiterates ~$21B 2022 sales outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $4.7B vs $4.4B YoY; GAAP net income $2.2B ($5.24 diluted EPS) vs $2.8B ($6.46) YoY.","Board authorizes new $3B share repurchase program; $1.9B used in H1 2022 repurchases.","2022 advance purchase agreements for COVID vaccine expected delivery ~$21B; Q4 sales seen > Q3.","Cost of sales 30% of product sales in Q2, including $499M inventory write-downs and $184M purchase commitment loss.","Four infectious disease vaccines in Phase 3; proof-of-concept data in rare diseases and immuno-oncology expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":13.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":10815000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373607,"accession_number":"0001193125-22-165220","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K/A","filed_at":"2022-06-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Moderna CFO David Meline to retire by Dec 31, 2022; will serve as consultant through Mar 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Meline continues as CFO until Dec 31, 2022 (or earlier if successor starts); consulting services to Mar 2, 2026.","Continued vesting in new hire equity award (to July 8, 2024), 2021 annual grant (to July 8, 2024), and 2022 annual grant (to Mar 2, 2026).","Prorated 2022 annual bonus at target; vested stock options extend 12 months after consulting period (not beyond original expiration).","Agreement supersedes April 10, 2022 retirement deal; includes non-disparagement, cooperation, and general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373612,"accession_number":"0001682852-22-000033","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moderna CEO Bancel amends 10b5-1 plan to exercise 4.6M options; expects to donate $355M proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Bancel amended 10b5-1 plan to exercise 4,587,155 shares at $0.99/share (option from 2013, expiring Aug 2023).","Exercise schedule: 40,000 shares each Wednesday and Thursday starting May 25, 2022, until fully exercised.","After-tax proceeds (~$355M at ~$140/sh) to be donated to charity; ~$280M in taxes paid.","Bancel's family entity OCHA LLC continues selling 10,000 shares each Thursday under separate 10b5-1 plan through end of 2022.","Bancel terminated prior 10b5-1 plans for gifts/sales in March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373606,"accession_number":"0001682852-22-000029","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K/A","filed_at":"2022-05-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Moderna enters separation agreement with former CFO; includes clawback tied to Dentsply probe","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jorge Gomez departed May 10; separation agreement signed May 13, 2022.","Severance of $700K salary (12 months) plus 12 months COBRA premium assistance.","Company can claw back benefits if Gomez is found to have engaged in wrongdoing or faces fines in Dentsply/SEC investigation.","Gomez released all claims against Moderna; non-compete waived; other restrictive covenants remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373611,"accession_number":"0001193125-22-146929","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Moderna CFO Jorge Gomez departs amid Dentsply Sirona investigation; David Meline returns as CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jorge Gomez terminated as CFO effective May 10, 2022, after former employer Dentsply Sirona disclosed an internal investigation.","David Meline, previously CFO from June 2020 to July 2021, resumes role effective May 11, 2022.","Gomez receives 12 months' salary ($700,000) and COBRA coverage; forfeits signing bonus, relocation, bonus, and new hire equity.","Meline retains annual salary of $700,000, 90% bonus target, and full vesting of 2022 equity awards previously set to forfeit on retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373610,"accession_number":"0001682852-22-000020","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moderna Q1 revenue $6.1B, net income $3.7B; reiterates $21B 2022 APAs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS of $8.58 vs $2.84 YoY; revenue tripled to $6.1B from $1.9B.","Cost of sales 17% of product sales; R&D $554M, SG&A $268M.","Cash, equivalents, and investments $19.3B at quarter end; operating cash flow $2.8B.","Four programs in Phase 3 in Q2: Omicron bivalent COVID booster, flu, RSV, CMV.","CFO David Meline retiring; Jorge Gomez appointed CFO effective May 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":8.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6066000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373609,"accession_number":"0001682852-22-000016","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moderna shareholders elect directors, approve executive compensation, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Noubar Afeyan (231.4M for), Stéphane Bancel (246.8M for), François Nader (234.2M for); broker non-votes 34.7M.","Advisory vote on named executive officer compensation passed with 277.97M for (93% of votes cast).","Ratification of Ernst & Young as auditor for FY2022 passed with 251.9M for (76% of votes cast).","Shareholder proposal requesting report on IP transfer feasibility failed with 70.9M for (24% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373608,"accession_number":"0001193125-22-101074","cik":1682852,"company_name":"Moderna, Inc.","ticker":"MRNA","form_type":"8-K","filed_at":"2022-04-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Moderna appoints Jorge Gomez as CFO; David Meline to retire effective May 9, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jorge Gomez appointed CFO effective May 9, 2022, reporting to CEO Stéphane Bancel.","Gomez previously CFO at Dentsply Sirona (Nasdaq: XRAY) and held CFO roles at Cardinal Health.","Current CFO David Meline retiring; will serve as consultant through July 2024 with continued equity vesting.","Gomez receives $700k base salary, $500k signing bonus, and equity grant valued at $4M vesting over four years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18486271851.834282,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-04-11T23:59:59+00:00|373608"}